1-(6-甲基-3-吡啶)哌嗪 | 845617-33-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(6-甲基-3-吡啶)哌嗪
• 中文别名: 6-甲基-吡啶-N-哌啶
• 英文名称: 1-(6-Methylpyridin-3-YL)piperazine
• CAS: 845617-33-6
• 化学式: C₁₀H₁₅N₃
• 分子量: 177.25
• InChiKey: OQQGPLUJVKMDEB-UHFFFAOYSA-N

物化性质

• 沸点：
  334.9±37.0 °C(Predicted)
• 密度：
  1.059±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

文献信息

• Benzoyl-piperazine derivatives
  申请人：Jolidon J. Synese

  公开号：US20050209241A1

  公开（公告）日：2005-09-22

  The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

  本发明涉及具有以下通式的化合物 其中取代基如本文所述。这些化合物可用于治疗基于抑制甘氨酸摄取的疾病，如精神疾病、疼痛、记忆和学习方面的神经退行性功能障碍、精神分裂症、痴呆症以及认知过程受损的其他疾病，例如注意力缺陷障碍或阿尔茨海默病。
• [EN] INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS<br/>[FR] COMPOSÉS D'INDOLINONE SERVANT D'INHIBITEURS DE MAP4K1
  申请人：ICHNOS SCIENCES S A

  公开号：WO2020070331A1

  公开（公告）日：2020-04-09

  The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring C, X1, X2, L1, R1, R2, R3, R4, R5, R6, R7, m and n are as defined herein, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.

  本公开涉及式(I)的化合物及其药用盐，其中环A、环C、X1、X2、L1、R1、R2、R3、R4、R5、R6、R7、m和n如本文所定义，这些化合物可用作MAP4K1抑制剂，其制备方法，包含这些化合物的药物组合物，以及这些化合物或组合物在治疗或预防由MAP4K1介导的各种疾病、症状和/或紊乱中的用途。
• [EN] 1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES<br/>[FR] DERIVES DE 1-(2-AMINO-BENZOL)-PIPERAZINE EN TANT QU'INHIBITEURS DE L'ABSORPTION DU GLYCOCOLLE POUR TRAITER DES PSYCHOSES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005023260A1

  公开（公告）日：2005-03-17

  A compound of formula (I) wherein the substituents are described in claim 1 for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

  具有式（I）的化合物，其中取代基如权利要求1中所述，用于治疗精神病、疼痛、记忆和学习中的神经退行性功能障碍、精神分裂症、痴呆症以及认知过程受损的其他疾病，如注意力缺陷障碍或阿尔茨海默病。
• [EN] PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS<br/>[FR] PIPERAZINE AVEC GROUPE PHENYLE SUBSTITUE DE TYPE OR ET LEUR UTILISATION COMME INHIBITEURS DE GLYT1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005014563A1

  公开（公告）日：2005-02-17

  The invention relates to compounds of formula (I) wherein the substituents are described in claim 1. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

  该发明涉及式（I）化合物，其中取代基如权利要求书中所述。这些化合物可用于治疗基于甘氨酸摄取抑制剂的疾病，如精神病、疼痛、记忆和学习中的神经退行性功能障碍、精神分裂症、痴呆症以及其他认知过程受损的疾病，如注意力缺陷障碍或阿尔茨海默病。
• BENZOYL-PIPERAZINE DERIVATIVES
  申请人：Jolidon Synese

  公开号：US20080119486A1

  公开（公告）日：2008-05-22

  The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

  本发明涉及化合物的公式，其中取代基如下所述。该化合物可用于治疗基于甘氨酸摄取抑制剂的疾病，例如精神病、疼痛、记忆和学习中的神经退行性功能障碍、精神分裂症、痴呆和其他认知过程受损的疾病，例如注意力缺陷障碍或阿尔茨海默病。